Novo Nordisk cut its 2025 guidance and outgoing CEO blames the compounding market for it.
Novo Nordisk outgoing CEO blames compounded GLP-1s for decline in 2025 outlook
July 29, 2025
You may also like
Indices by TradingView
Oracle soars 30% on cloud growth projections even as earnings miss estimates
September 10, 2025
Rezolve Ai Highlights Significant Valuation Discount vs. Leading AI Peers
September 10, 2025
1 Warren Buffett Quote That Makes Me Excited to Buy Nvidia Stock
September 10, 2025
Categories
Indices by TradingView